Highbridge Capital Management LLC bought a new position in Teladoc Health Inc (NYSE:TDOC) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 14,500 shares of the health services provider’s stock, valued at approximately $963,000.

Other hedge funds have also recently modified their holdings of the company. Jennison Associates LLC increased its position in Teladoc Health by 60.6% in the 2nd quarter. Jennison Associates LLC now owns 1,172,135 shares of the health services provider’s stock worth $77,841,000 after purchasing an additional 442,140 shares during the last quarter. Manchester Capital Management LLC acquired a new position in shares of Teladoc Health during the 1st quarter valued at about $75,000. Aperio Group LLC increased its holdings in shares of Teladoc Health by 28.3% during the 2nd quarter. Aperio Group LLC now owns 7,170 shares of the health services provider’s stock valued at $476,000 after acquiring an additional 1,582 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Teladoc Health by 5.9% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 583,858 shares of the health services provider’s stock valued at $38,775,000 after acquiring an additional 32,535 shares during the last quarter. Finally, GAM Holding AG acquired a new position in shares of Teladoc Health during the 1st quarter valued at about $2,243,000.

TDOC opened at $72.15 on Friday. The stock’s 50 day moving average price is $63.17 and its two-hundred day moving average price is $61.38. The company has a quick ratio of 7.56, a current ratio of 7.56 and a debt-to-equity ratio of 0.43. Teladoc Health Inc has a 12-month low of $42.08 and a 12-month high of $89.05.

Teladoc Health (NYSE:TDOC) last released its earnings results on Wednesday, July 31st. The health services provider reported ($0.41) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.40) by ($0.01). The business had revenue of $130.30 million during the quarter, compared to analyst estimates of $129.54 million. Teladoc Health had a negative net margin of 21.85% and a negative return on equity of 10.64%. The business’s quarterly revenue was up 37.8% compared to the same quarter last year. During the same period last year, the business earned ($0.40) EPS. On average, sell-side analysts anticipate that Teladoc Health Inc will post -1.56 EPS for the current year.

In other Teladoc Health news, insider Lewis Levy sold 675 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $70.00, for a total value of $47,250.00. Following the completion of the sale, the insider now owns 4,805 shares in the company, valued at approximately $336,350. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Andrew Turitz sold 9,158 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $62.27, for a total value of $570,268.66. Following the completion of the sale, the senior vice president now owns 6,827 shares of the company’s stock, valued at approximately $425,117.29. The disclosure for this sale can be found here. Insiders sold a total of 115,046 shares of company stock worth $7,811,011 in the last ninety days. Insiders own 3.95% of the company’s stock.

A number of research analysts have recently commented on TDOC shares. Svb Leerink reissued an “outperform” rating on shares of Teladoc Health in a report on Thursday, August 1st. SunTrust Banks increased their price objective on Teladoc Health to $80.00 and gave the company a “positive” rating in a report on Tuesday, August 6th. Jefferies Financial Group reissued a “buy” rating and set a $95.00 price objective on shares of Teladoc Health in a report on Tuesday, July 2nd. Craig Hallum increased their price objective on Teladoc Health from $70.00 to $80.00 and gave the company a “buy” rating in a report on Thursday, August 1st. Finally, JPMorgan Chase & Co. increased their price objective on Teladoc Health from $82.00 to $83.00 and gave the company an “overweight” rating in a report on Thursday. Three investment analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $82.60.

About Teladoc Health

Teladoc Health, Inc provides telehealth services. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

Featured Article: Dead Cat Bounce

Want to see what other hedge funds are holding TDOC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teladoc Health Inc (NYSE:TDOC).

Institutional Ownership by Quarter for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.